Extended Data Figure 1. SLC7A11expression is downregulated by p53 and identification of p53 binding sites for mouse Slc7a11gene.

a, Messenger RNA levels of SLC7A11 in tet-on wild-type p53 stable line and parental H1299 cells treated with doxycycline (0.1 μg ml⁻¹). b, U2OS cells were treated with doxorubicin (0.2 μg ml⁻¹) and mRNA was quantified. c, Osteosarcoma cell lines, U2OS (p53 wild type) and SAOS-2 (p53 null) cells, were treated with doxorubicin (0.2 μg ml⁻¹) and mRNA levels were determined. d, Lung cancer cell lines, H1299 (p53 null) and H460 (p53 wild type) cells, were treated with doxorubicin (0.2 μg ml⁻¹) and RT–PCR was used to determine mRNA expression. e, The breast cancer cell line MCF7 was treated with doxorubicin (0.2 μg ml⁻¹) for indicated duration and RT–qPCR was used to measure mRNA expression. f, RT–qPCR were used to determine the mRNA level of Slc7a11 in MEFs with indicated genotype. g, Schematic diagram representing potential p53 binding locations and sequences on the mouse Slc7a11 gene. TSS, transcription start site; light blue box, 5′-UTR. h, ChIP–qPCR was performed on MEFs that were treated with nutlin (10 μM) for 6 h. All qPCR was performed in two technical replicates and mean ± s.d. are shown. All experiments were repeated independently three times.